Hana Biosciences Announces Issuance of Talotrexin Patent
2006年2月14日 - 10:30PM
ビジネスワイヤ(英語)
Hana Biosciences (AMEX:HBX), a biopharmaceutical company focused on
advancing cancer care, announced today the issuance of U.S. Patent
No. 6,989,386 on January 24, 2006, from the U.S. Patent and
Trademark Office. U.S. Patent No. 6,989,386 is directed to
Talotrexin compositions and methods of using Talotrexin
compositions. The Company believes the patent significantly
strengthens its Talotrexin intellectual property estate. "We are
thrilled to have a very strong patent position for our lead
product, Talotrexin, and expect additional patents to issue,
positioning us with a very firm intellectual property estate,"
commented Mark Ahn, PhD., President & Chief Executive Officer.
About Talotrexin Talotrexin (PT-523) is a novel nonpolyglutamatable
antifolate drug which has demonstrated enhanced antitumor activity
in a broad spectrum of cancers by targeting DHFR to prevent DNA
synthesis and inhibit tumor growth. Compared to currently available
antifolates such as methotrexate or pemetrexed (Alimta(R); Eli
Lilly) in preclinical studies, Talotrexin enters into cells up to
10-times more efficiently, demonstrated 10 to 100 fold more potency
by overcoming resistance by remaining active in tumors by not
requiring polyglutamation, and binds more tightly to its anti-tumor
target DHFR which enhances efficacy. Thus, a Phase I trial in solid
tumors, Phase I/II in NSCLC (non-small cell lung cancer), and a
Phase I/II in ALL (acute lymphocytic leukemia) are ongoing. Phase
II trials in cervical, endometrial and ovarian cancers are
forthcoming. About Hana Biosciences, Inc. Hana Biosciences, Inc.
(AMEX:HBX) is a South San Francisco, CA-based biopharmaceutical
company that acquires, develops, and commercializes innovative
products to advance cancer care. The company is committed to
creating value by building a world-class team, accelerating the
development of lead product candidates, expanding its pipeline by
being the alliance partner of choice, and nurturing a unique
company culture. Additional information on Hana Biosciences can be
found at www.hanabiosciences.com. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements involve
risks and uncertainties that could cause Hana's actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions that are
subject to risks and uncertainties, which could cause actual
outcomes and results to differ materially from these statements.
Among other things, there can be no assurances that any of Hana's
development efforts relating to its product candidates will be
successful. Other risks that may affect forward-looking information
contained in this press release include the possibility of being
unable to obtain regulatory approval of Hana's product candidates,
the risk that the results of clinical trials may not support Hana's
claims, Hana's reliance on third-party researchers to develop its
product candidates, and its lack of experience in developing
pharmaceutical products. Additional risks are described in the
company's Annual Report on Form 10-KSB for the year ended Dec. 31,
2004. Hana assumes no obligation to update these statements, except
as required by law.
Hana Biosciences (AMEX:HBX)
過去 株価チャート
から 5 2024 まで 6 2024
Hana Biosciences (AMEX:HBX)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Hana Biosciences (アメリカ証券取引所): 0 recent articles
その他のHana Biosciencesニュース記事